Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and if they point to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Management (Ric Fulop and James Haley) discuss: - Record revenue, growth, gross margin expansion. - Strategic integration and cost optimization initiative announced in June, with $40 million annualized savings, $20 million in H2 2022, and at least $100 million over 24 months. This is a cost-cutting initiative already executed (workforce reduction, facility consolidation, product portfolio evaluation). The benefit is still ahead (H2 2022 and beyond). This is a concrete, already-executed change to the operating machine whose benefit is arriving. Management says: "We expect this strategic initiative to drive $40 million of annualized run rate non-GAAP cost savings, $20 million of which we expect to recognize in the second half of 2022." And "As a result of these efforts, Desktop Metal is a more streamlined business today with an improved go-forward expense structure that better position us to reach our financial commitments and support a path to profitability." So they have done something (cost cuts) and the payoff is ahead. - Also, they mention FreeFoam, a new product, but that's not yet commercially available (broad commercial availability in 2023). So not already operating. - They mention IP monetization effort, but that's just started, not concrete. - They mention customer wins, but those are ongoing. - They mention the convertible notes offering in May, which strengthens cash position. That's already done, but its contribution is more about balance sheet, not earnings. Now, does management convey that outsiders are currently underweighting something? They don't explicitly say "the market is underweighting our cost cuts" or "analysts are not modeling our cost savings." They do say they are focused on profitability and have taken actions. But is there a recognition gap? They mention "I was disappointed in our expense spend" in the previous quarter, and now they've taken action. But they don't say that the market is not giving credit for something already done. They reaffirm guidance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.